Turtle Cameron sold $1.4M of SYRE
Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $92.01 ($89.14–$93.91, $1.38M total) across 6 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the CEO's ownership, which may be interpreted by investors as a lack of confidence, potentially prompting short‑term selling pressure.
Market read
The filing is a primary source of insider activity, offering modest trading relevance for SYRE investors.
What to watch
Potential upcoming clinical data releases or partnership announcements that could offset the negative sentiment from the insider sale.
Background
Form 4 filings provide the first public disclosure of insider transactions. This filing reports a CEO‑initiated sale under a pre‑arranged 10b5‑1 plan.
Ticker impact
CEO Turtle Cameron sold 15,000 shares for $1.38M via a 10b5-1 plan, reducing his stake to 537,540 shares.
likely pressure as the market prices in the insider sell
A $1.38M sale by the CEO is a material insider transaction but modest in size for a micro‑cap; markets typically react modestly negative to such sales.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
No regional effect; confined to SYRE shareholders.
Low global relevance.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals, so the stock may be undervalued if the market overreacts.
Key entities
- personTurtle Cameron
Chief Executive Officer of Spyre Therapeutics, Inc.
- companySpyre Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
